Back to News
Market Impact: 0.2
Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright
Source: marketbeat.com
Healthcare & BiotechProduct LaunchesCorporate Guidance & Outlook
Abeona Therapeutics highlighted early commercial progress for ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa, at the H.C. Wainwright 28th Annual Conference. The update signals initial commercialization momentum for the rare-disease gene therapy, though no revenue, patient-treatment, or guidance figures were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ABEO0.45
More News
- Trump Says US Team Met With Iranians at UNGA
- Paramount will need to release way more movies to make this merger work
- Meta is breaking out after introducing Muse AI agent. Where the stock is going, according to the charts
- Meta’s Muse AI is exploding in popularity—and already drawing heated backlash from another tech giant
- Royal Caribbean nears $3 billion deal to take 50% equity stake in Sandals
- Meta's quick success with Muse puts consumers back in the driver's seat of the AI trade